Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain

Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain

The artemin-GFRα3 signaling pathway has been implicated in various painful conditions including migraine, cold allodynia, hyperalgesia, inflammatory bone pain, and mouse knees contain GFRα3-immunoreactive nerve endings. We developed high affinity mouse (REGN1967) and human (REGN5069) GFRα3-blocking...

Full description

Bibliographic Details
Main Authors: Selin Somersan-Karakaya, Kenneth C. Turner, Luz Cortes-Burgos, Jutta Miller, Michael LaCroix-Fralish, Veronika Logovinsky, Yamini Patel, Richard Torres, Samit Ganguly, Aurora Breazna, Michelle DeVeaux, Rafia Bhore, Min Gao, Frank J. Delfino, Ashique Rafique, Jeanette L. Fairhurst, Charleen Hunt, Robert Babb, Ashok Badithe, William T. Poueymirou, Ronald Surowitz, Sylvie Rottey, Andrew J. Murphy, Olivier Harari, Lynn E. Macdonald, Susan D. Croll
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Neurobiology of Pain
Subjects:
REGN5069
GFRα3
GFRα3-artemin signaling
Osteoarthritis pain
Online Access:http://www.sciencedirect.com/science/article/pii/S2452073X23000235

Similar Items

Similar Items